NCT01673594View on ClinicalTrials.gov

Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
ADHDStimulant-Induced Euphoria
Interventions
DRUG

SODAS MPH

Adults with ADHD will receive open-label SODAS MPH

DRUG

Naltrexone

"Subjects randomized to the active double-blind group will receive Naltrexone HCl"

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Massachusetts General Hospital

OTHER

NCT01673594 - Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist | Biotech Hunter | Biotech Hunter